TRPV6 Knockout cell line (BeWo)

Gene knockout cell lines are generated using CRISPR-Cas9 based technology to precisely disrupt target genes, enabling functional genomics research, disease modeling, and target validation.

The BeWo cell line was established from a malignant gestational choriocarcinoma of the fetal placenta and represents the first human trophoblastic endocrine cell type maintained in continuous culture. The cells exhibit trophoblastic characteristics and produce high levels of human chorionic gonadotropin (hCG), along with other placental hormones including placental lactogen and steroid hormones such as estrone, estradiol, estriol, and progesterone. BeWo cells can undergo cellular differentiation in response to hormonal precursors and are widely used as an in vitro model for studying trophoblast biology, placental hormone regulation, and mechanisms of placental development and function.

Each knockout cell line is validated by STR authentication, sterility testing (bacteria/fungi), and mycoplasma screening. Genotype is confirmed by two rounds of PCR and Sanger sequencing. Only clones that pass all QC criteria are released, ensuring reliable identity and performance for downstream applications.